1. Introduction {#Section1}
===============

Cardiovascular diseases (CVDs) remain a major killer of human health and accord for the growing mortality and disability in developed countries and some developing countries such as China. Stem cells-based therapy showed great promise to regenerate damaged myocardium and treat CVDs. Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs) and adipose tissue-derived stem cells (ADSCs) have shown therapeutic potential on CVDs and suggested as ideal sources of stem cells-based therapy [@B1]. In particular, MSCs transplantation has been proved as a new promising therapeutic approach for CVDs because MSCs possess multipotent differentiation ability and paracrine actions. MSCs originally derive from mesoderm and ectoderm during early embryonic development, and were found in various types of tissues and organs such as bone marrow [@B2], fat [@B3], muscles [@B4], lungs [@B5], liver [@B6], pancreas [@B7] and synovial membrane [@B8]. MSCs are capable to differentiate into osteoblasts [@B9], adipocytes [@B10], chondrocytes [@B11], CMCs [@B12], endothelial cells (ECs) [@B13] and vascular smooth muscle cells (VSMCs) [@B14] after the induction of certain microenvironments and cellular factors *in vitro* or *in vivo*. It has been widely recognized that engrafted MSCs differentiating into CMCs at least to a certain degree accounts for therapeutic effects of MSCs transplantation [@B15]. In addition to cardiomyocyte differentiation, MSCs are also capable to differentiate into ECs and VSMCs, which contributed to revascularization [@B16]-[@B18]. Accordingly, transplanted MSCs can replace the loss of vascular cells and CMCs in myocardial infarction (MI) and heart failure, and improved cardiac function of damaged hearts [@B19]-[@B21]. Whereas actually, it has been observed that only a minority of MSCs survived and engrafted after transplantation, and most of MSCs do not differentiate into CMCs, ECs and VSMCs to exert potent therapeutic effects. It suggests that MSCs might exert biological functions through multiple mechanisms.

Increasing evidence demonstrated that MSCs also can secrete functional paracrine factors such as vascular endothelial growth factor (VEGF), insulin-like growth factor-1 and basic fibroblast growth factor to produce various protective effects such as promoting vascular regeneration [@B22], supporting hematopoiesis [@B23], repairing injured kidney [@B24], facilitating myocardial repair [@B25] and ameliorating cardiac remodeling [@B26]. Interestingly, recent study revealed that transplanted MSCs may secret abundant particles documented as exosomes, which not only may reduce tissue injury but also enhance tissue repair [@B27]. Exosomes are cholesterol-rich, phospholipid vesicles enriched with microRNAs (miRNAs) which have been well recognized to regulate gene expression in a post-transcriptional manner and play a prominent role in various pathological and physiological processes [@B28]-[@B29] (Fig. [1](#F1){ref-type="fig"}). In the light of protective influences of exosomes on cardiovascular system, it is proposed that exosomes secreted by MSCs will be presented as an ideal therapeutic target for CVDs in the near future.

2. Exosomes {#Section2}
===========

2.1. Concept and characteristic of exosomes {#Section2.1}
-------------------------------------------

Exosomes are defined as nanosized membrane vesicles with a diameter of 30-100 nm that origins from multivesicular endosomal and are released by cells into extracellular environment. It is different from the other extracellular vesicles (EVs)---microvesicles which has a diameter of 100-1000 nm and origins from plasma membrane. It has been reported that there are multiple contents in exosomes including cytokines, proteins, lipids, mRNAs, miRNAs and ribosomal RNAs [@B30]-[@B31]. Exosomes can be released by various cells including T cells [@B32], B cells [@B33], reticulocytes [@B34], mast cells [@B35], platelets [@B36] and tumor cells [@B37]-[@B38]. For instance, miR-126 secreted from chronic myelogenous leukemia cells was found shuttled into endothelial cells, which modulated adhesive and migratory abilities of chronic myelogenous leukemia cells [@B39]. The exosomes derived from chronic myelogenous leukemia stimulated interleukin-8 (IL-8) release from bone marrow stromal cells, and promoted the progression of leukemia [@B40]. Thus, exosomes are suggested as central mediators of intercellular communication by transferring proteins, mRNAs and miRNAs to adjacent cells leading to coordinative function in organisms [@B41]-[@B42].

2.2. Exosomes secreted by MSCs {#Section2.2}
------------------------------

Likewise, MSCs also synthesize and secrete functional exosomes that are cholesterol-rich phospholipid vesicles. For example, bone marrow-derived MSCs may release the exosomes that can promote breast cancer cell dormancy in a metastatic niche [@B43]. Adipose MSCs secret the exosomes and microvesicles, and in turn regulate angiogenic potential of MSCs [@B44]. Gastric cancer tissue-derived MSCs also may release exosomes [@B45]. Moreover, injection of exosomes from MSCs into stroke rats might relieve symptoms by promoting angiogenesis, neurite remodeling and neurogenesis [@B46]. The exosomes derived from MSCs contain lipids, protein, mRNAs, precursor miRNAs (pre-miRNAs), miRNAs, etc. In particular, miRNAs in microparticles were sensitive to RNase only with the existence of phospholipase A2, sodium dodecyl sulfate-based cell lysis buffer or cyclodextrin, which definitely indicates that direct protection of RNAs against RNase was afforded by cholesterol-rich phospholipid vesicles [@B29].

2.3. miRNAs mediated functions of exosomes {#Section2.3}
------------------------------------------

It is well known that miRNAs play an essential role in various physiological and pathological processes by regulating gene expression at the post-transcription level [@B47]. The primary miRNAs (pri-miRNAs) are transcribed by RNA polymerase II and then are excised into pre-miRNAs by Drosha. Then, pre-miRNAs are cleaved by Dicer into mature miRNAs that assemble with argonaute (Ago) protein to form miRNA-induced silencing complex (RISC). It was recently reported that the exosomes with a hydrodynamic radius of 55\~65nm were rich in miRNAs, and the majority form of miRNAs was not mature but pre-miRNAs [@B29]. Pre-miRNAs are also able to exert biological effects after the conversion into mature miRNAs. The loading and secretion of miRNAs in exosomes have been ascertained as a strictly controlled process dependent on the source and developmental stage of derived cells rather than a random process.

Recent studies have clearly clarified that miRNAs mediate biological effects of exosomes on a variety of tissues [@B45], [@B49]. For example, MSCs-derived exosomes lead to a significant inhibition of angiogenesis through miR-16-mediated downregulation of VEGF in breast cancer cells [@B48]. Gastric cancer tissue-derived mesenchymal stem cells were shown to promote growth and migration of gastric cancer via transferring exosomal miR-221 [@B45]. In cardiovascular system, miRNAs-bearing exosomes or microvesicles are readily internalized into CMCs and ECs, resulting in cardiomyocyte protection and angiogenesis promotion [@B49]-[@B50]. These studies uncover important roles of miRNAs encapsulated in exosomes in the development of CVDs.

3. Effects of exosomes on cardiovascular system {#Section3}
===============================================

3.1. Cardiac benefits of exosomes {#Section3.1}
---------------------------------

### Anti-apoptosis

Myocardial infarction is characterized by progressive loss of CMCs consequently resulting in congestive heart failure (CHF), and has become a difficult challenge due to the failure of CMCs to replace apoptotic cells. Emergence of MSCs provides a novel approach for therapeutics of MI not only because of their capability to directly differentiate into CMCs but also their anti-apoptotic effect from paracrine action [@B49], [@B51]-[@B52].

Recent study has reported that MSCs had ability to ameliorate ischemic CMCs injury by transferring miR-22 in exosomes targeting methyl CpG binding protein 2 (Mecp2) to reduce apoptosis [@B52] (Fig. [2](#F2){ref-type="fig"}). Moreover, delivery of miR-221 in exosomes mediated anti-apoptotic effect of MSCs by inhibiting p53-upregulated modulator of apoptosis (PUMA), a subclass of the Bcl-2 protein family [@B49]. PUMA was shown to interplay with BCL-xL and p53 [@B53], and activate pro-apoptotic proteins while restrain anti-apoptotic proteins, so inhibition of PUMA by miR-221 could give rise to CMCs survival [@B49]. These findings suggest that miRNAs-bearing exosomes are involving in anti-apoptotic process.

### Anti-inflammatory effect

It is well known that exosomes from dendritic cells, MHC class II+ cells and tumor cells aggressively participate in inhibition of inflammation response, which is considered as a novel therapeutic approach for some diseases [@B54]-[@B56]. Likewise, some studies have also proved that exosomes derived from MSCs indeed produce similar benefits on CVDs [@B57]-[@B58]. It was revealed that suppression of inflammation by MSCs-derived exosomes in lungs accords for relieving symptoms of pulmonary hypertension (PH) [@B57]. Additionally, it was also reported that MSCs-secreting exosomes contributed to a smaller number of white blood cell count and alleviated inflammation reaction accompanied by decreased infarct size and enhanced cardiac function in hearts after ischemia-reperfusion injury (IRI) [@B58] (Fig. [2](#F2){ref-type="fig"}). These studies reveal MSCs-derived exosomes exert protective effects against CVDs through inhibition of inflammation reaction.

### Anti-cardiac remodeling

Cardiac remodeling, a compensatory consequence of CVDs such as myocardial hypertrophy and fibrosis, usually develops into heart failure without proper treatments [@B59]. Autologous MSCs transplantation has been shown to reduce infarct size, improve left ventricular ejection fraction (LVEF) and reverse remodeling after chronic myocardial infraction [@B60]. Recent study uncovered that exosomes derived from MSCs was able to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia-reperfusion injury via activating pro-survival signaling, restoring bioenergetics and reducing oxidative stress [@B58]. Though anti-cardiac remodeling effect of MSCs-derived exosomes was confirmed, mechanisms of exosomes-mediated protection have not been verified.

### Cardiac regeneration

Necrosis and apoptosis of CMCs due to pathological microenvironment or damaged factors is causal to heart failure while conventional therapies such as medications, surgeries and even intervention have certain limitations. Cardiac regeneration by MSCs and cardiac stem cells (CSCs) differentiation is raised as a novel strategy for curing CVDs [@B61]-[@B63]. It has been found that MSCs had ability to induce endogenous cardiac regeneration [@B28] (Fig. [2](#F2){ref-type="fig"}). MVs and exosmes released by cardiomyocyte progenitor cells (CPCs) could induce cardiac regeneration and improve cardiac function by promoting migration of ECs and secretion of VEGF resulting in angiogenesis [@B64]-[@B65]. The combination of human MSCs and human cardiac stem cells have a better impact on the reduction of infarct size and improve cardiac functions than MSCs alone [@B66]. However, whether exosomes take part in cardiac regeneration of MSCs still remains unclear, and the role of exosomes in cardiac regeneration needs further investigations.

3.2. Vascular benefits of exosomes {#Section3.2}
----------------------------------

### Neovascularization

Neovascularization is one of multiple effects of exosomes involving arteriogenesis, vasculogenesis and angiogenesis which are associated with proliferation and migration of ECs and VSMCs, differentiation into ECs and VSMCs, and formation of ECs from formerly existing vessels [@B28], [@B67]. Exosomes from placental mesenchymal stem cells (pMSCs) induced by hypoxia are major participator in facilitating migration and vascularization of placental microvascular endothelial cells (PMEC) [@B67]. Adipose mesenchymal stem cells (ASCs) can secret extracellular vesicles including both exosomes and microvesicles, which are critical for angiogenesis both *in vitro* and *in vivo* following internalization by human microvascular endothelial cells (HMECs), while platelet-derived growth factor (PDGF) strengthens this positive influence by means of irritating ASCs to release exosomes and microvesicles which are rich in pro-angiogenic molecules [@B44] (Fig. [3](#F3){ref-type="fig"}). Exosomes released by human umbilical cord MSCs under hypoxic condition deliver mRNAs and miRNAs to target cells, and promote proliferation of umbilical cord endothelial cells (Fig. [3](#F3){ref-type="fig"}), therefore leading to angiogenic action, enhanced blood flow restoration and capillary network formation [@B50]. Exosomes secreted by MSCs are implicated in the stimulation of tumor growth via upregulating VEGF level in tumor cells and consequent angiogenic effect, but it also has been reported the property of MSCs-derived exosomes to inhibit angiogenic process in breast cancer tissues [@B48], [@B68]. Heterogeneity of MSCs, dosage of MSCs administration, tumor types and impurity of MSCs might be responsible for inverse impacts of MSCs-derived exosomes on the development of tumor [@B69].

### Anti-vascular remodeling

Vascular remodeling is an adaptive reaction in response to hemodynamic changes involving hyperplasia, hypertrophy, apoptosis and migration of vascular cells as well as generation and degradation of extracellular matrix [@B70]-[@B74]. Some documents reported that paracrine activity is responsible for anti-vascular remodeling effect of MSCs in rats suffering from pulmonary hypertension by inhibiting Smad2, which is indicated by reduced pulmonary arterial pressure and symptoms amelioration [@B72]. Notably, MSCs-derived exosomes have been recently shown to block expression of hypoxia-induced mitogenic factor (HIMF) induced by hypoxia to inhibit proliferation, and it suggests MSCs-derived exosomes play an essential role in anti-vascular remodeling [@B57],[@B73]-[@B74] (Fig. [3](#F3){ref-type="fig"}). But molecular mechanisms of anti-vascular remodeling effect of MSCs-derived exosomes need to be defined precisely.

3.3. Roles of exosomes in MSCs therapy of CVDs {#Section3.3}
----------------------------------------------

### Myocardial infarction (MI)

MI, a detrimental consequence of acute or persistent coronary occlusion, is featured by myocardial necrosis and cardiomyocyte loss [@B75]. It has been revealed that MSCs transplantation into infarcted region is able to improve cardiac function, and this efficacy could be enhanced in the case of MSCs modification with upregulation of miR-1 by promoting MSCs survival and differentiation into CMCs [@B76]. Interestingly, exosomes derived from MSCs contain the increased amount of miR-22 under ischemic condition, and can be centralized to CMCs to protect against apoptosis by miR-22 targeting Mecp2. Moreover, cardiac fibrosis is also antagonized by exosomes, which indicates exosomes-mediating critical protection for MI [@B52]. So, it was proposed that there exists a feed-forward loop network mediated by exosomes between ischemic hearts and other tissues: exosomes released by damaged myocardium transfer proteins and miRNAs which include ischemic signal to distant tissues or organs such as bone marrow (BM), leading to changes in the microenvironment of BM after MI; At the same time, exosomes from adjusted BM and progenitor cells are also delivered back to ischemic regions to trigger regeneration and repair processes [@B77].

### Reperfusion injury

It is well documented that ischemia-reperfusion may result in irreversible structural damage and dysfunction of organs, which would be greatly attributed to generation of excessive free radicals [@B78]. In spite of Vitamin E and its analogues discovered as ideal antioxidants against ischemia-reperfusion injury, few studies refer to relevant applications in clinical trials [@B79]-[@B81]. Hopefully, great interest has arisen in the consideration of MSCs as a prospective agent for ischemia-reperfusion injury due to involvement of MSCs in both myogenesis and angiogenesis to generate protective effects including reduction of infarct size, remarkable amelioration of left ventricular performance and increased amount of capillary vessels [@B82]. Intact exosomes secreted by MSCs were found to reduce oxidative stress, increase ATP and NADH, control inflammatory activities and activate PI3K/Akt pathway, leading to protective influences on CMCs survival and retention of left ventricular function after ischemia-reperfusion injury, which indicates exosomes as a supplemental entity for ischemia-reperfusion therapy [@B58].

### Pulmonary hypertension

PH is a kind of malignant pulmonary vascular diseases and characterized by an increase in pulmonary artery pressure, which may lead to right heart failure and even death. Pulmonary inflammation induced by hypoxia and bronchopulmonary dysplasia induced by hyperoxia may account for the development of PH [@B57], [@B83]. Administration of MSCs has been proved to confer a better prognosis of PH than medicines applied in clinics now, and has been widely tested in PH rats to uncover its underlying mechanisms [@B84]-[@B85].

PH following pulmonary vascular remodeling is highly correlated with pulmonary inflammation caused by hypoxia [@B57], [@B86]. MSCs-derived exosomes (MEX) treatment directly suppress activation of hypoxic signal pathway and then result in interference with alternative activated alveolar macrophages by targeting Th1/Th2 balance and down-regulation of proliferative miR-17 superfamily by shifting the balance of proliferation to inhibit PH. Moreover, MEX might disturb STAT3-miR-204-STAT3 feedback to ameliorate vascular remodeling. The findings above elucidate that MEX are protective for PH through the suppression of early pulmonary inflammation and vascular remodeling [@B57].

4. Exosomes as a new therapeutic strategy for CVDs {#Section4}
==================================================

The above studies reveal that MSCs-derived exosomes play an essential role in MSCs-based therapy of CVDs including MI, reperfusion injury and PH. The detailed mechanisms underlying benefits of exosomes in MSCs transplantation of these CVDs require further investigations. Administration of exosomes from MSCs instead of MSCs transplantation has displayed therapeutic potential on CVDs including increasing survival of cardiomyocytes as well as to inhibiting apoptosis. Thus, exosomes derived from MSCs represents a promising approach for the treatment of CVDs [@B58]. Compared to traditional MSCs therapies, MSCs-exosomes therapies will decrease injury from MSCs transplantation surgery, avoid the risk of unexpected differentiation into other cell types such as osteoblasts, adipocytes and chondrocytes as well as vascular calcification, and reduce possibility of favoring tumor growth by MSCs. Accordingly, administration of *in vitro* purified MSCs-derived exosomes becomes more attractive than conventional stem cells transplantation. Effects of MSCs-derived exosomes on cardiovascular system should be largely attributed to functional cytokines, miRNAs and proteins in exosomes. Nevertheless, how to preserve biological activity of cytokines, miRNAs and proteins in exosomes and deliver them to target sites is a big challenge for us now [@B30]. Following investigations are needed to solve the troubles of MEX therapy and make MEX become a promising entity for CVDs.

5. Conclusions {#Section5}
==============

Much interest has been generated in exploring the role of exosomes in stem cell-based therapy of CVDs since they were discovered. Transferring characteristic of exosomes suggests its involvement in regulating cell-to-cell communication [@B87]-[@B89]. Notably, the possibility of exosomes as a diagnostic biomarker in clinics has been proposed due to their derived cell developmental stage-dependent and source-dependent features [@B90]. Though MEX possess more advantages than MSCs for CVDs therapy, further investigations are required to explore detailed mechanisms of generation, secretion, shuttle and action of MSCs-derived exosomes. Exosomes will be a new promising therapeutic strategy for CVDs in the future.
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![Mechanisms of mesenchymal stem cells transplantation for CVDs. MSCs can differentiate into CMCs, ECs and VSMCs to replace the loss of cardiovascular cells. Besides, MSCs also secreted paracrine factors and exosomes to target heart and vasculature to exert anti-apoptosis, anti-cardiac remodeling, anti-inflammatory reactions, neovascularization and anti-vascular remodeling effects.](ijbsv11p0238g001){#F1}

![Exosomes mediates beneficial effects of MSCs on hearts. MSCs secret exosomes containing miR-22 and miR-221 to target Mecp2 and PUMA, and thus exert anti-apoptotic effects. Anti-inflammatory effect of MSCs is mediated by exosomes as well as MVs. Exosomes are also responsible for anti-cardiac remodeling of MSCs. Cardiac regeneration property of MSCs has been proved, but whether exosomes are involved in this process remains unclear.](ijbsv11p0238g002){#F2}

![Effects of MSCs on vasculature. MSCs secrete exosomes to facilitate PMECs migration, and thus contribute to vascularization. Angiogenic action of MSCs is mediated by MSCs-secreting EVs and MVs. MSCs generate exosomes and paracrine factors to inhibit HIMF and Smad2, and exert anti-vascular remodeling effect.](ijbsv11p0238g003){#F3}
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Origins and functions of exosomes derived from mesenchymal stem cells.

![](ijbsv11p0238g004)

[^1]: Competing Interests: The authors have declared that no competing interest exists.
